Merck gets lift from U.S. patent office in battle over injectable form of Keytruda

Taking stock of the drug industry, from the lab to the medicine chest

June 4, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Good evening. This week only, get 50% off your first year of STAT+ and enjoy unlimited access to award-winning journalism, premium data tools, discounted event tickets, and much more. Thanks for reading.

Adobe STAT+ | Merck gets lift from U.S. patent office in battle over injectable form of Keytruda The PTO decision to review the patent "likely reduces the probability" that Halozyme will prevail, said Wells Fargo analyst Mohit Bansal. By Ed Silverman STAT+ | FDA's AI tool, Elsa, is here. 'The stupidest big fuss they ever made' In this edition of STAT's AI Prognosis: FDA's AI tool, Elsa was launched across the agency weeks ahead of shcedule, and more health AI news. By Brittany Trang STAT+ | These blood tests for cancer are increasingly popular. Experts still aren't sure how best to use them Liquid biopsy tests grow in use and show promise in cancer detection, but experts say more trials are needed on the clinical benefit of ctDNA testing. By Angus Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser